

## SmartBreast buys molecular breast imaging assets from GE Healthcare

February 8, 2021 | News

**The Discovery NM750b is installed at scores of sites worldwide**



SmartBreast Corporation (SmartBreast™), a privately held company with headquarters near Pittsburgh, US and offices in Los Angeles, US and Taipei, Taiwan, focused on breast cancer screening and diagnosis, has announced that it has acquired the Discovery NM750b Molecular Breast Imaging (MBI) assets from GE Healthcare, including the MBI scanner designs, manufacturing tools, instructions, related patents and the installed-base service business.

The Discovery NM750b is installed at scores of sites worldwide. SmartBreast will manufacture, market and distribute the MBI scanner, rebranded as "EVE CLEAR SCAN e750."

MBI saves lives by detecting breast cancer earlier in women with dense breasts, who comprise about 40% of American, European and African women and 70% of Asian women. MBI sees through dense breast tissue and finds cancers that mammography misses.

"GE Healthcare's MBI system has developed a positive reputation for helping physicians with the detection of cancer lesions in dense breast tissue," says Erez Levy, General Manager of Nuclear Medicine, GE Healthcare. "We are proud of this system's legacy and will continue to support its mission with our world-class Cadmium Zinc Telluride (CZT) detectors for SmartBreast's use in the MBI system"